261 related articles for article (PubMed ID: 12742996)
1. Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action.
Kalinowski L; Dobrucki LW; Szczepanska-Konkel M; Jankowski M; Martyniec L; Angielski S; Malinski T
Circulation; 2003 Jun; 107(21):2747-52. PubMed ID: 12742996
[TBL] [Abstract][Full Text] [Related]
2. Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol.
Dessy C; Saliez J; Ghisdal P; Daneau G; Lobysheva II; Frérart F; Belge C; Jnaoui K; Noirhomme P; Feron O; Balligand JL
Circulation; 2005 Aug; 112(8):1198-205. PubMed ID: 16116070
[TBL] [Abstract][Full Text] [Related]
3. Nebivolol: a highly selective beta1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide.
Gupta S; Wright HM
Cardiovasc Ther; 2008; 26(3):189-202. PubMed ID: 18786089
[TBL] [Abstract][Full Text] [Related]
4. Nebivovol and carvedilol induce NO-dependent coronary vasodilatation that is unlikely to be mediated by extracellular ATP in the isolated guinea pig heart.
Kozlovski VI; Lomnicka M; Chlopicki S
Pharmacol Rep; 2006; 58 Suppl():103-10. PubMed ID: 17332679
[TBL] [Abstract][Full Text] [Related]
5. Nitric oxide mechanisms of nebivolol.
Maffei A; Lembo G
Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):317-27. PubMed ID: 19443516
[TBL] [Abstract][Full Text] [Related]
6. The favorable kinetics and balance of nebivolol-stimulated nitric oxide and peroxynitrite release in human endothelial cells.
Mason RP; Jacob RF; Corbalan JJ; Szczesny D; Matysiak K; Malinski T
BMC Pharmacol Toxicol; 2013 Sep; 14():48. PubMed ID: 24074014
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic dose of nebivolol, a nitric oxide-releasing beta-blocker, reduces atherosclerosis in cholesterol-fed rabbits.
de Nigris F; Mancini FP; Balestrieri ML; Byrns R; Fiorito C; Williams-Ignarro S; Palagiano A; Crimi E; Ignarro LJ; Napoli C
Nitric Oxide; 2008 Aug; 19(1):57-63. PubMed ID: 18435936
[TBL] [Abstract][Full Text] [Related]
8. The role of P2Y-receptors in the regulation of glomerular volume.
Jankowski M; Szczepańska-Konkel M; Kalinowski L; Angielski S
Med Sci Monit; 2001; 7(4):635-340. PubMed ID: 11433188
[TBL] [Abstract][Full Text] [Related]
9. Effect of nebivolol on endothelial nitric oxide and peroxynitrite release in hypertensive animals: Role of antioxidant activity.
Mason RP; Kubant R; Jacob RF; Walter MF; Boychuk B; Malinski T
J Cardiovasc Pharmacol; 2006 Jul; 48(1):862-9. PubMed ID: 16891916
[TBL] [Abstract][Full Text] [Related]
10. Acute effects of third generation β-blockers on short-term and beat-to-beat blood pressure variability in sinoaortic-denervated rats.
Bertera FM; Del Mauro JS; Lovera V; Chiappetta D; Polizio AH; Taira CA; Höcht C
Hypertens Res; 2013 Apr; 36(4):349-55. PubMed ID: 23364340
[TBL] [Abstract][Full Text] [Related]
11. Experimental evidences of nitric oxide-dependent vasodilatory activity of nebivolol, a third-generation beta-blocker.
Ignarro LJ
Blood Press Suppl; 2004 Oct; 1():2-16. PubMed ID: 15587107
[TBL] [Abstract][Full Text] [Related]
12. Radical scavenging and NO-releasing properties of selected beta-adrenoreceptor antagonists.
Szajerski P; Zielonka J; Sikora A; Adamus J; Marcinek A; Gebicki J; Kozlovski VI; Drelicharz L; Chłopicki S
Free Radic Res; 2006 Jul; 40(7):741-52. PubMed ID: 16984001
[TBL] [Abstract][Full Text] [Related]
13. Different pharmacological properties of two enantiomers in a unique beta-blocker, nebivolol.
Ignarro LJ
Cardiovasc Ther; 2008; 26(2):115-34. PubMed ID: 18485134
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms underlying nebivolol-induced endothelial nitric oxide synthase activation in human umbilical vein endothelial cells.
Ladage D; Brixius K; Hoyer H; Steingen C; Wesseling A; Malan D; Bloch W; Schwinger RH
Clin Exp Pharmacol Physiol; 2006 Aug; 33(8):720-4. PubMed ID: 16895546
[TBL] [Abstract][Full Text] [Related]
15. Nebivolol: a third-generation beta-blocker that augments vascular nitric oxide release: endothelial beta(2)-adrenergic receptor-mediated nitric oxide production.
Broeders MA; Doevendans PA; Bekkers BC; Bronsaer R; van Gorsel E; Heemskerk JW; Egbrink MG; van Breda E; Reneman RS; van Der Zee R
Circulation; 2000 Aug; 102(6):677-84. PubMed ID: 10931809
[TBL] [Abstract][Full Text] [Related]
16. Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart.
Rozec B; Erfanian M; Laurent K; Trochu JN; Gauthier C
J Am Coll Cardiol; 2009 Apr; 53(17):1532-8. PubMed ID: 19389564
[TBL] [Abstract][Full Text] [Related]
17. Effect of nebivolol, a novel beta 1-selective adrenoceptor antagonist with vasodilating properties, on kidney function.
Greven J; Gabriëls G
Arzneimittelforschung; 2000 Nov; 50(11):973-9. PubMed ID: 11148863
[TBL] [Abstract][Full Text] [Related]
18. Carvedilol ameliorates endothelial dysfunction in streptozotocin-induced diabetic rats.
Fu GS; Huang H; Chen F; Wang HP; Qian LB; Ke XY; Xia Q
Eur J Pharmacol; 2007 Jul; 567(3):223-30. PubMed ID: 17559835
[TBL] [Abstract][Full Text] [Related]
19. Characterization of nitric oxide release by nebivolol and its metabolites.
Maffei A; Vecchione C; Aretini A; Poulet R; Bettarini U; Gentile MT; Cifelli G; Lembo G
Am J Hypertens; 2006 Jun; 19(6):579-86. PubMed ID: 16733229
[TBL] [Abstract][Full Text] [Related]
20. [Role of the L-arginine/nitric oxide system in the action of nebivolol].
Brodde OE; Philipp T
Dtsch Med Wochenschr; 2006 Nov; 131(45):2545-50. PubMed ID: 17091442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
